Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic
08:08am, Thursday, 02'nd Nov 2023
Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a senior
7 A-Rated Tech Stocks to Buy for November
06:40am, Thursday, 02'nd Nov 2023
Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to lea
Novo Nordisk: obesity drugs priority over century-old focus on insulin
06:38am, Thursday, 02'nd Nov 2023
Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from its
Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record Profits
06:26am, Thursday, 02'nd Nov 2023
Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.
Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies
04:34am, Thursday, 02'nd Nov 2023
Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.
Novo Nordisk shares higher on bumper Wegovy boost
04:17am, Thursday, 02'nd Nov 2023
Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy. Novo Nordisk (NYSE:NVO) said sales of obesity medication incr
Novo Nordisk flags continued restrictions on Wegovy supplies
02:39am, Thursday, 02'nd Nov 2023
Novo Nordisk on Thursday reported record sales and operating profits for the third quarter but flagged continued restrictions on supplies of its hugely popular Wegovy weight-loss drug.
Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drugs.
05:00pm, Wednesday, 01'st Nov 2023
The earnings report comes amid what has been a surprisingly grim two weeks for the pharmaceutical stocks.
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
02:17pm, Wednesday, 01'st Nov 2023
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source
01:14pm, Wednesday, 01'st Nov 2023
Novo Nordisk has hired FUJIFILM Diosynth Biotechnologies to fill Wegovy injection pens, a source familiar with the matter told Reuters, as the Danish drugmaker scrambles to boost output of its hugely
Should You Buy Novo Nordisk (NVO) Ahead of Earnings?
12:02pm, Wednesday, 01'st Nov 2023
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Novo Nordisk makes its weight-loss drug Wegovy
06:18am, Wednesday, 01'st Nov 2023
Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy.
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
09:30am, Sunday, 29'th Oct 2023
Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could also address hypertension, so the potential market could be huge.
3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K
08:25am, Friday, 27'th Oct 2023
Over the past 100 years, the stock market has proved to be the best way to build wealth. Even through recessions, depressions, and world wars, growth stocks generate better returns than any other asse
Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.
07:44am, Wednesday, 25'th Oct 2023
Novo Nordisk has reported strong revenue and profit growth over the past five years. The company recently upgraded its guidance for 2023.
